Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
